DelveInsight Sitemap

All Static Pages
ID Pages Priority Action
1 Home Page 1.0 Visit Page
2 Blog Page 0.9 Visit Page
3 About Us 0.9 Visit Page
4 pipline 0.8 Visit Page
5 BIO Us Event 0.8 Visit Page
6 BIO Taiwan Event Page 0.8 Visit Page
7 BIO Pharm Event 2019 0.8 Visit Page
8 BIO Japan 2019 0.8 Visit Page
9 Bio Europe 2019 Event 0.8 Visit Page
10 PharmDelve 0.9 Visit Page
11 Contact Us 0.7 Visit Page
12 DelveInsight Register 0.9 Visit Page
13 Whitepaper/Newsletter 0.9 Visit Page
14 Press Release 0.9 Visit Page
15 case study 0.9 Visit Page
16 Careers 0.9 Visit Page
17 Events 0.9 Visit Page
18 Market Research 0.9 Visit Page
19 Report Sore 0.9 Visit Page
20 Consulting 0.9 Visit Page
21 Case Study Asset Prioritization 0.8 Visit Page
22 Case Study : Out Licensing Opportunity - Success Stories 0.8 Visit Page
23 Case Study : In Licensing Opportunity - Success Stories 0.8 Visit Page
24 Case Study : Go to Market Strategy - Success Stories 0.8 Visit Page
25 Launch Landscape Analysis 0.8 Visit Page
26 Case Study : Product Assessment - Success Stories 0.8 Visit Page
27 Asset Prioritizaton Services 0.8 Visit Page
28 business development services 0.8 Visit Page
29 Competitive Intelligence Services 0.8 Visit Page
30 Licensing Services 0.8 Visit Page
31 Merger and Acquisition 0.8 Visit Page
32 Partner Identification Services 0.8 Visit Page
33 Competitive Benchmarking Services 0.8 Visit Page
34 Pharmaceutical Portfolio Management Solutions 0.8 Visit Page
35 R&D Analysis 0.8 Visit Page
36 Market Assessment Services 0.8 Visit Page
37 Regulatory Analysis Services 0.8 Visit Page
38 Due Diligence Services 0.8 Visit Page
39 Terms and Conditions 0.7 Visit Page
40 Privacy Policy 0.7 Visit Page
41 Case study - portfolio management 0.8 Visit Page
42 Case Study - Pipeline Assessment Consulting Services 0.8 Visit Page
43 impact-of-brexit-on-pharma-space 0.7 Visit Page
44 Case Study - Due Diligence Consulting Services 0.8 Visit Page
45 Event - Bio Asia-Taiwan 2019 0.6 Visit Page
46 Case Study - Partner Identification Consulting Services 0.8 Visit Page
47 Case Study - Regulatory Analysis Consulting Services 0.8 Visit Page
48 cancer-in-the-united-states-vol-1-issue-2 0.8 Visit Page
49 cancer-globally-vol-1-issue-1 0.8 Visit Page
50 COVID 19 0.9 Visit Page
51 An Abundance of Rare 0.9 Visit Page
52 Pompe Disease Newsletter 0.9 Visit Page
53 Fragile X Syndrome Newsletter | FXS Newsletter 0.9 Visit Page
54 Sitemap 0.9 Visit Page
56 Cutaneous Lupus Erythematosus Newsletter 0.9 Visit Page
57 Duchenne Muscular Dystrophy Newsletter | DMD Newsletter 0.9 Visit Page
58 Complex Regional Pain Syndrome Newsletter | CRPS Newsletter 0.9 Visit Page
59 Gaucher Disease Newsletter | Gaucher Disease Market 0.9 Visit Page
60 Mergers and Acquisitions Case study 0.9 Visit Page
61 Case study - Competitive Benchmarking 0.8 Visit Page
62 Case Study - R&D Analysis 0.8 Visit Page
63 CEO Message on CoronaVirus 0.9 Visit Page
64 Specialised Reports 0.9 Visit Page
65 Pipeline Insight 0.9 Visit Page
66 Mechanism of Action 0.9 Visit Page
67 Epidemiology Insight 0.9 Visit Page
68 Drug Insight 0.9 Visit Page
69 Drug API Insight 0.9 Visit Page
70 Competitive Landscape 0.9 Visit Page
71 Global API Manufacturers, Marketed and Phase III Drugs Landscape 0.9 Visit Page
72 ASCO Conference 0.9 Visit Page
73 ASCO Day 1 0.9 Visit Page
74 Day 2 ASCO 0.9 Visit Page
75 FOP Newsletter 0.9 Visit Page
76 Paroxysmal Nocturnal Hemoglobinuria 0.9 Visit Page
77 Precision Medicine 0.9 Visit Page
78 Relapse/ Refractory Patients in Haematological Malignancies 0.9 Visit Page
79 ASCO All 0.9 Visit Page
80 404 0.6 Visit Page
81 Day 3 ASCO 0.9 Visit Page
82 BIO EUROPE WINTER 2019 0.9 Visit Page
83 BIO Japan 2020 0.7 Visit Page
84 COVID 19 Whitepaper 0.9 Visit Page
86 Advance Search 0.7 Visit Page
87 RAYNAUD’S PHENOMENON Newsletter 0.9 Visit Page
88 infographics 0.9 Visit Page
89 Focal Segmental Glomerulosclerosis Newsletter 0.9 Visit Page
90 Healthcare Performance Whitepaper 0.9 Visit Page
91 Adult Onset Still's Disease Newsletter 0.9 Visit Page
92 Prader-Willi syndrome Newsletter 0.9 Visit Page
94 Familial chylomicronemia syndrome Newsletter 0.9 Visit Page
95 Hereditary ATTR (hATTR) Amyloidosis Newsletter 0.9 Visit Page
96 Neuroendocrine tumors Newsletter 0.9 Visit Page
97 Retinitis Pigmentosa Newsletter 0.9 Visit Page
98 Ataxia Telangiectasia Newsletter 0.9 Visit Page
99 Chronic Inflammatory Demyelinating Polyneuropathy Newsletter 0.9 Visit Page
100 The Ophthalmic Drug Delivery Therapeutics For Retinal Disorders Whitepaper 0.9 Visit Page
101 Digital Health Transformation: 2020 Roadmap For Innovation Whitepaper 0.9 Visit Page
102 Von Hippel-Lindau (VHL) syndrome Newsletter 0.9 Visit Page
103 Exocrine Pancreatic Insufficiency Newsletter 0.9 Visit Page
104 Warm Autoimmune Hemolytic Anemia (WAIHA) Newsletter 0.9 Visit Page
105 Digital Therapeutics in Mental Health Whitepaper 0.9 Visit Page
106 Cancer Care in the time of COVID Whitepaper 0.9 Visit Page
107 Current Treatment Challenges of IO Refractory Patients and Clinical Development of Therapies Targeting These Patients Whitepaper 0.9 Visit Page
108 Immune Thrombocytopenic Purpura (ITP) Newsletter 0.9 Visit Page
109 ESMO Conference 2020 0.9 Visit Page
ASCO Conference Profile Pages
ID Pages Priority Action
1 Pfizer’s TALA (talazoparib) in metastatic castration-resistant prostate cancer (mCRPC) 0.8 Visit Page
2 AstraZeneca and Merck’s Lynparza (olaparib) in Metastatic Castration-resistant Prostate Cancer (mCRPC) 0.8 Visit Page
3 Bayer Healthcare and Orion's Nubeqa (darolutamide) in Non-metastatic castration-resistant prostate cancer (nmCRPC) 0.8 Visit Page
4 Roche’s Ipatasertib (RG7440) in Metastatic Castration-resistant Prostate Cancer (mCRPC) 0.8 Visit Page
5 GSK has a strong say in ASCO 2020 as they are announcing key data on Cell Therapy and Next-generation Immuno-oncology 0.8 Visit Page
6 Can much awaited JAVELIN data give any surprise in ASCO 2020? 0.8 Visit Page
7 Another new combination approaches for front line multiple myeloma may bring a new option to patients 0.8 Visit Page
8 How effectively microsatellite instability-high/mismatch repair can be used for proper positioning in the Colorectal Cancer treatment landscape? 0.8 Visit Page
9 Another win for blockbuster Osimertinib (in an early stage of EGFR NSCLC) will further strengthen its potential in Lung Cancer 0.8 Visit Page
10 KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative... 0.8 Visit Page
11 Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)... 0.8 Visit Page
12 PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2... 0.8 Visit Page
13 Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOT... 0.8 Visit Page
14 Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, doubleblinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breas... 0.8 Visit Page
15 A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triplenegative breast cancer (mTNBC) (ENHANCE 1). 0.8 Visit Page
16 Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer. 0.8 Visit Page
17 A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. 0.8 Visit Page
18 SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC)... 0.8 Visit Page
19 Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer. 0.8 Visit Page
20 A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metas... 0.8 Visit Page
21 Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (H... 0.8 Visit Page
22 Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast canc... 0.8 Visit Page
23 Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: (DART=Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors) (SWOG S1609, Cohort 36). 0.8 Visit Page
24 A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlatio... 0.8 Visit Page
25 A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC) 0.8 Visit Page
26 IMvigor130 results might support the usage of combination of atezolizumab +/- platinum/gemcitabine as an important new treatment option for patients with untreated mUC. 0.8 Visit Page
27 Another missed trial of the ASCO 2020 as Adjuvant treatment with the PD-L1 inhibitor did not significantly improve disease-free survival (DFS) in patients with muscle-invasive bladder cancer 0.8 Visit Page
28 Promising results from IMbrave150 TRIAL of Atezolizumab + Bevacizumab may shift the treatment paradigsm for advanced HCC 0.8 Visit Page
29 Good clinical response for dual immune checkpoint inhibitors (Tremelimumab + Durvalumab) in second line HCC however, tough fight ahead in first line setting from much promising Atezolizumab + Bevacizu... 0.8 Visit Page
30 Long term follow up of Lifileucel treatment in a heavily pretreated metastatic melanoma patients who progressed on multiple prior therapies, including anti-PD1 and BRAF/MEK inhibitors 0.8 Visit Page
31 Future directions for Head and Neck treatment based on TMB studies 0.8 Visit Page
32 Long term follow up study of the use of pembrolizumab and its combination as first line treatment for recurrent/metastatic head and neck cancer 0.8 Visit Page
33 Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irino... 0.8 Visit Page
34 Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longerterm follow-up of the phase II, KEYNOTE-164 study. 0.8 Visit Page
35 Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical... 0.8 Visit Page
36 A Phase II, multicenter, open-label study of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer 0.8 Visit Page
37 Interim analysis of ZUMA-5: A phase II study of axi-cel in pts with R/R iNHL 0.8 Visit Page
38 Lisocabtagene maraleucel (liso-cel) for treatment of 2L TNE R/R aggressive large B-cell NHL 0.8 Visit Page
39 Effect of enasidenib plus azacitidine (AZA) on Complete and overall response versus AZA monotherapy in mutant-IDH2 newly diagnosed AML 0.8 Visit Page
40 Tolerability and efficacy of anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML: Phase Ib results 0.8 Visit Page
41 Glasdegib plus low-dose cytarabine in AML or MDS: BRIGHT AML 1003 final report and four-year OS follow-up 0.8 Visit Page
42 Five year results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML 0.8 Visit Page
43 6 month update: Phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with AML (VIALE-C) 0.8 Visit Page
44 Long-term survivors and gilteritinib safety post 1 year in FLT3-mutated R/R AML: ADMIRAL trial 0.8 Visit Page
45 Glasdegib in combination with azacitidine in patients with untreated higher-risk MDS, AML and CMML: Effects on marrow recovery and transfusion independence 0.8 Visit Page
46 CC-486 is safe and well-tolerated as maintenance therapy in patients >75 years with AML in first remission following induction chemotherapy: Phase III QUAZAR AML-001 trial 0.8 Visit Page
47 HRQoL in the phase III QUAZAR-AML-001 trial of CC-486 as maintenance therapy for patients with AML in first remission following induction chemotherapy 0.8 Visit Page
48 Venetoclax + intensive chemo with CLIA achieves high rates of durable complete remission with low rates of MRD in pts with newly diagnosed AML 0.8 Visit Page
49 Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk MDS 0.8 Visit Page
50 Phase I study of teclistamab, a dual-targeting immunotherapeutic, in relapse/refractory Multiple Myeloma 0.8 Visit Page
51 Initial results from phase III BOSTON study, comparing weekly selinexor + Vd versus twice weekly Vd in patients with R/R multiple myeloma 0.8 Visit Page
52 Initial KarMMa results : bb2121, a BCMA-targeted CAR T-cell therapy, in R/R multiple myeloma patients 0.8 Visit Page
53 Phase 1/2 update from EVOLVE study : orva-cel, a BCMA- directed CAR T cell therapy for patients with R/R multiple myeloma 0.8 Visit Page
54 Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of antiCD22 activity 0.8 Visit Page
55 Safety and efficacy results of GC027: The first-in-human, universal CART cell therapy for adult r/r T-ALL 0.8 Visit Page
56 Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a BCMA-directed CAR-T-cell therapy, in R/R multiple myeloma 0.8 Visit Page
57 Primary analysis of phase II trial of VRd with/without elotuzumab for newly diagnosed multiple myeloma (SWOG-1211). 0.8 Visit Page
58 Depth of response to isatuximab + KRd (Isa-KRd) in front-line treatment of multiple myeloma: Interim analysis of the GMMG-CONCEPT trial 0.8 Visit Page
59 Updates from BELLINI, a phase III study of venetoclax or placebo in combination with Vd in R/R multiple myeloma 0.8 Visit Page
60 Selinexor, daratumumab, and dexamethasone in patients with R/R multiple myeloma 0.8 Visit Page
61 VRd superiority to lenalidomide, adriamycin, and dexamethasone (RAd) prior to risk-adapted transplant in newly diagnosed myeloma 0.8 Visit Page
62 Phase III TOURMALINE-MM4 : Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma patients not undergoing ASCT 0.8 Visit Page
63 DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with R/R multiple myeloma refractory to PI, IMiD, and anti-CD38 mAb 0.8 Visit Page
64 BELLINI study : Evaluation of MRD in R/R multiple myeloma patients treated with venetoclax or placebo with Vd 0.8 Visit Page
65 DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with Vd in R/R multiple myeloma 0.8 Visit Page
66 First-in-human data of ALLO-501 and ALLO-647 in R/R LBCL/FL: ALPHA study 0.8 Visit Page
67 Comparison of efficacy and safety with obinutuzumab plus chemo vs. rituximab plus chemo in patients with previously untreated FL: Updates from phase III Gallium Study 0.8 Visit Page
68 First-line immunochemotherapy for FL in the GALLIUM study: Prognostic value of PET-CT status after long-term follow-up 0.8 Visit Page
69 Bosutinib for CP-CML after imatinib failure: 8-year update 0.8 Visit Page
70 Independent review: Arterial occlusive events due to ponatinib in PACE trial Ph+ CML 0.8 Visit Page
71 Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analyses from the BYOND study 0.8 Visit Page
72 KEYNOTE-204: Phase III study of Pembrolizumab vs Brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma 0.8 Visit Page
73 HALO Trial: Brentuximab vedotin and bendamustine as first-line treatment of Hodgkin lymphoma in the elderly 0.8 Visit Page
74 Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients. 0.8 Visit Page
75 Gls-010 in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Impressive Phase II Results 0.8 Visit Page
76 Long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell NHL and CLL 0.8 Visit Page
77 Safety and efficacy of optimized tandem CD19/CD20 CAR-engineered T cells in patients with R/R NHL 0.8 Visit Page
78 Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL 0.8 Visit Page
79 Phase I study of AUTO3 with pembrolizumab in patients with r/r DLBCL 0.8 Visit Page
80 Epcoritamab (GEN3013) to induce CR in pts with R/R B-NHL: Complete dose escalation data and efficacy results from a phase I/II trial 0.8 Visit Page
81 Retreatment of pts with refractory DLBCL with axi-cel in ZUMA-1 0.8 Visit Page
82 Final results of Lenalidomide plus R-GDP (R2-GDP) - GOTEL in relapsed/refractory diffuse large B-cell lymphoma 0.8 Visit Page
83 RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy in transplant-ineligible pts with R/R DLBCL 0.8 Visit Page
84 Outpatient treatment with liso-cel across a variety of clinical sites from three ongoing clinical studies in R/R LBCL. 0.8 Visit Page
85 Atezolizumab + obinutuzumab + venetoclax in patients with R/R DLBCL: Primary analysis of a phase II trial from LYSA 0.8 Visit Page
86 Finally Opdivo in combination with Yervoy has got success in much awaited lucrative first line NSCLC patients whose tumors express PD-L1≥1% and approval is further supported by long term data 0.8 Visit Page
87 Wthin a space of 11 days, Opdivo-Yervoy with chemo bagged another approval in first line NSCLC irrespective of PD-L1 expression 0.8 Visit Page
88 Frontline durvalumab and tremelimumab combo misses overal survival endpoint in metastatic NSCLC 0.8 Visit Page
89 Another new combination of tiragolumab and atezolizumab has shown efficacy signals in lucrative first line NSCLC 0.8 Visit Page
90 Novartis unveils more capmatinib data from GEOMETRY mono-1 study 0.8 Visit Page
91 Osimertinib trial results in NSCLC patients with EGFR exon 20 insertions from ECOG-ACRIN 5162 trial 0.8 Visit Page
92 Roche presented long term data of alectinib from ALEX study in frontline advanced ALK+ NSCLC 0.8 Visit Page
93 Another MET inhibitor expected to make their way in METex14+ mutated NSCLC 0.8 Visit Page
94 Novartis presented the data from GEOMETRY mono-1 study to support the capmatinib usage in second line setting 0.8 Visit Page
95 Takeda published brigatinib data from J-ALTA study to supprt its approval in Japanese patients 0.8 Visit Page
96 Heat Biologics's allogeneic cellular vaccine in combination with nivolumab shown efficacy signals in phase I/II data 0.8 Visit Page
97 Pembrolizumab usage along with radiothreapy associated with better efficacy outcomes 0.8 Visit Page
98 Merck presented the data from VISION study to support its FDA approval in patients with NSCLC with METex14 skipping 0.8 Visit Page
99 Two year follow up data of bintrafusp alfa presented by Merck with encouraging efficacy signals 0.8 Visit Page
100 CheckMate 568 Part 2 data will further support the approval of nivolumab plus ipilimumab with two cycles of chemotherapy combo in firstline NSCLC setting 0.8 Visit Page
101 Pegilodecakin did not show any improvement in efficacy when added to pembrolizumab in first line NSCLC 0.8 Visit Page
102 Data from exploratory RELAY+ study of ramucirumab plus gefitinib supports its usage in first line EGFR mutated NSCLC 0.8 Visit Page
103 Phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter’s syndrome 0.8 Visit Page
104 Good interim data from phase 2 trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC 0.8 Visit Page
105 Initial results of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax 0.8 Visit Page
106 Novartis presented Phase II data of one more promising irreversible 3rd-generation EGFR TKI 0.8 Visit Page
107 TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions 0.8 Visit Page
108 Acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL: ASCEND final results 0.8 Visit Page
109 Final data of KEYNOTE-189 study in patients with newly diagnosed metastatic nonsquamous NSCLC 0.8 Visit Page
110 Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib + trametinib in patients with BRAF V600E mutant metastatic NSCLC 0.8 Visit Page
111 Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC 0.8 Visit Page
112 Effect of adding ublituximab to ibrutinib on efficacy in previously treated high-risk CLL: GENUINE phase III study 0.8 Visit Page
113 Some supporting data of Lorlatinib; irreversible 3rd-generation EGFR TKI in patients with ALK-positive NSCLC 0.8 Visit Page
114 Mute response of Durvalumab trial as Durvalumab plus tremelimumab fails to show the clinical activity in patients with acquired resistance to PD-1 checkpoint inhibitors 0.8 Visit Page
115 Acalabrutinib in treatment-naïve CLL: Mature results from Ph II study demonstrating durable remissions and longterm tolerability 0.8 Visit Page
116 Fixed-duration venetoclax-obinutuzumab for previously untreated pts with CLL: Follow-up results from phase III CLL14 trial 0.8 Visit Page
117 Supportive data from Nivolumab trial for its use as monotherapy or in combination with cisplatin/carboplatin and etoposide as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC) 0.8 Visit Page
118 Phase III MURANO study results: Impact of premature venetoclax discontinuation/interruption on outcomes in R/R CLL 0.8 Visit Page
119 Consistent result of tazemetostat in terms of Efficacy, safety, and immune priming effect in patients with epithelioid sarcoma. 0.8 Visit Page
120 Eribulin and pembrolizumab disappointed with its efficacy results in Uterine leiomyosarcoma (LMS) 0.8 Visit Page
121 Role of CDK4/6 inhibitors in treating advanced Soft Tissue Sarcoma (STS) 0.8 Visit Page
122 Highest reported efficacy of doxorubicin + pembrolizumab till date in a preliminary advanced STS trial 0.8 Visit Page
123 AKT inhibition by Ipatasertib in mCRPC: The A.MARTIN Randomized Phase II trial 0.8 Visit Page
124 Updated results from ARAMIS phase III trial showed darolutamide improves overall survival (OS) over placebo in nmCRPC patients 0.8 Visit Page
125 Updated overall survival results from PROSPER: A phase III, randomized, double-blind, placebo controlled study of enzalutamide (ENZA) in men with nmCRPC 0.8 Visit Page
126 Apalutamide Plus ADT Leads to Significantly Improved Outcomes in Nonmetastatic CRPC: Results from the phase III SPARTAN trial 0.8 Visit Page
127 Novel AKT inhibitor fails to demonstrate a difference in the primary outcome of PFS: Results from phase II ProCAID trial 0.8 Visit Page
128 Pembrolizumab plus enzalutamide in patients with abiraterone acetate pretreated mCRPC: KEYNOTE-365 cohort C efficacy, safety, and biomarker results 0.8 Visit Page
129 HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer 0.8 Visit Page
130 Impact of Olaparib vs Physician’s Choice of New Hormonal Agent On Burden of Pain in mCRPC: Results from PROfound 0.8 Visit Page
131 AstraZeneca presented the Health-related quality of life (HRQoL) data for olaparib versus enzalutamide or abiraterone in mCRPC with HRR gene alterations 0.8 Visit Page
132 Exelixis reports data from Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With mCRPC 0.8 Visit Page
133 Pfizer has presented the positive interim data of PARP inhibitor from the TALAPRO-1 phase II trial 0.8 Visit Page
134 Data from CARD study Confirm Benefit of Cabazitaxel Over Abiraterone or Enzalutamide in mCRPC 0.8 Visit Page
135 Much awaited result of Trastuzumab + trimodality treatment for HER2+ esophageal adenocarcinoma brought disappointment with its failure in reaching the primary end point 0.8 Visit Page
136 No significant survival benefit of pembrolizumab over 2L paclitaxel in previusly treated PD-L1+ advanced gastric or gastroesophageal junction cancer 0.8 Visit Page
137 Tumor mutational burden (TMB) demonstrates a positive association with clinical outcomes with pembrolizumab in gastric cancer 0.8 Visit Page
138 Another PD-1 inhibitor (Sintilimab) jointly developed by Innovent and Eli Lilly has met its primary endpoint of overall survival in the second-line treatment of patients with metastatic esophageal squ... 0.8 Visit Page
139 In gastric cancer no treatment till date has shown such a strong data, Definately Enhetru will be positioned much ahead of Kadcyla 0.8 Visit Page
140 A rare failure of Olaparib brought a lot of disappointment for ovarian cancer patient community 0.8 Visit Page
141 Role of DOCK8, EP 400, and PDX1 mutations as prognostic biomarkers & its association with longer survival in patients treated with Selinexor. 0.8 Visit Page
142 Role of MDNA55 (Interleukin-4 Receptor) in a difficult to treat population (de novo GBM, IDH wild-type, not eligible for surgery at recurrence) & its benefit for patient resistant to temozolomide. 0.8 Visit Page
143 Another novel combination approach (INO-5401 + INO-9012 with Cemiplimab) for newly diagnosed GBM patients 0.8 Visit Page
144 Not so encouraging results for Atezolizumab in comination of Temozolomide for newly diagnosed GBM 0.8 Visit Page
145 Savolitinib can be a better treatment choice than sunitinib due to its improved efficacy and safety profile 0.8 Visit Page
146 Results from TIVO-3 supports use of Tivozanib for highly treatment refractory RCC patients 0.8 Visit Page
147 Not very promising but Cabozantinib is an effective treatment option for the patients with advanced refractory RCC 0.8 Visit Page
148 The result from KEYNOTE-426 warrants the use of pembrolizumab and axitinib as a standard of care for patients with previously untreated RCC 0.8 Visit Page
149 Lenvatinib plus Pembrolizumab shows strong data for mccRCC with disease progression following prior PD-1/PDL-1 therapy 0.8 Visit Page
150 Tumor Mutation Burden (TMB): One Size fits for all? Not really! 0.8 Visit Page
151 Lilly overthrows Pfizer in Early HR+/HER2- Breast Cancer, what Next? 0.8 Visit Page
152 ESMO 2020 – Major trials in focus and Our View Points 0.8 Visit Page
153 Triumphs and Troubles for Combination Therapies in Melanoma: COMBI-I Trial Failure Story 0.8 Visit Page
154 Will ADC’s be in focus in ESMO 2020 too? 0.8 Visit Page
155 BMS/Exelixis face-off with Merck’s Keytruda in front-line renal cancer 0.8 Visit Page
156 Gilead's ASCENT into Oncology: Sacituzumab results at ESMO 2020 0.8 Visit Page